Enovis (NYSE:ENOV) Trading Up 13.7% After Strong Earnings

Enovis Corporation (NYSE:ENOV) shot up 13.7% during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $25.31 and last traded at $25.38. 254,281 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 1,090,022 shares. The stock had previously closed at $22.32.

The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The business had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same period in the previous year, the business earned $0.98 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q4 adjusted earnings outpaced estimates — Enovis reported adjusted EPS of $0.95 (beat vs. ~$0.81 consensus), signaling underlying operating profitability despite GAAP noise. Enovis (ENOV) Q4 Earnings Beat Estimates
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.52–3.73, above Street expectations — that upward EPS range supports a higher valuation multiple and helped sentiment. Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Street support: BTIG boosted its price target and kept a Buy, and a notable fund added ~$5M to a position, both signaling conviction from some investors/analysts. Benzinga (BTIG price target raise) One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post‑Earnings
• Neutral Sentiment: Top‑line growth mixed: full‑year sales grew ~7% (2H momentum in Reconstructive) and Q4 net sales rose ~3%, showing commercial progress but not a breakout. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Adjusted metrics remain healthier: adjusted EBITDA and adjusted EPS show profitable operations (adjusted EBITDA/adj. EPS materially positive), which the company highlights as the basis for its guidance. QuiverQuant summary of Enovis results
• Negative Sentiment: Revenue missed Q4 consensus ($575.8M vs. ~$584M expected) and full‑year revenue guidance (~$2.31–2.37B) sits slightly below some Street views — a headwind for growth expectations. Enovis beats earnings but misses on revenue
• Negative Sentiment: Large non‑cash goodwill impairment ($501M Q4, $1.05B FY) produced a substantial GAAP net loss (Q4 and FY), weakening headline earnings, accumulated deficit and some balance‑sheet metrics — a risk for longer‑term investor confidence. QuiverQuant (impairment and GAAP loss details)

Analysts Set New Price Targets

ENOV has been the topic of a number of analyst reports. BTIG Research upped their price target on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Wells Fargo & Company increased their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Canaccord Genuity Group reduced their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, UBS Group reaffirmed a “buy” rating and set a $50.00 price objective on shares of Enovis in a research note on Monday, January 5th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Insider Transactions at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. McIlrath & Eck LLC raised its stake in shares of Enovis by 6.9% during the third quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock worth $167,000 after buying an additional 357 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Enovis by 6.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after acquiring an additional 495 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Enovis by 3.6% in the 3rd quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock valued at $509,000 after purchasing an additional 585 shares during the period. Finally, Heritage Family Offices LLP lifted its stake in shares of Enovis by 8.9% in the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock valued at $231,000 after purchasing an additional 620 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The company has a 50-day moving average price of $24.30 and a 200-day moving average price of $28.21. The firm has a market capitalization of $1.45 billion, a P/E ratio of -1.07 and a beta of 1.52.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.